Idéal Investisseur
Français English
CAC 40 :
8 157,82 pts
-0.84%


Last updated : 24/04/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

VALNEVA Shares Decline to €3.98, Marking a Weekly Drop of 8.42%

VALNEVA shares lose ground on Monday midday, trading at €3.98, showing a decline of 2.07% from Friday's close. This downturn is part of a more concerning trend: the stock has accumulated a decrease of 8.42% over seven days and 7.83% since the beginning of October, erasing most of its gains for the current month.


VALNEVA Shares Decline to €3.98, Marking a Weekly Drop of 8.42%

Monday's Session Highlights Fragility Despite Strong Annual Performance

Monday's session confirms the fragility of the situation, although annual performances remain strong. VALNEVA has risen by 84.26% since January 1st and shows a gain of 47.41% over twelve months, compared to 9.77% for the CAC 40. However, this divergence underscores an asymmetric volatility: on the flip side, the stock has plummeted by 8.42% in just one week, revealing less solid foundations than it seems. The last three months remain positive at 22.92%, and the six months show a progress of 25.82%, but this momentum is visibly eroding. The trading activity remains very restrained, with only 0.28% of capital exchanged, indicating restrictive liquidity and tempered interest. The stock is approaching its support level identified at €3.78, creating a critical tension zone, while the major resistance remains distant at €5.09. This highly compressed range between support and resistance translates into a pronounced phase of indecision. Regarding valuations, the consensus of analysts displays a three-month target price of €6.85, implying an upside potential of 69.73%. Nevertheless, earnings forecasts reflect tension: the net earnings per share would be -€0.48 for 2025 against -€0.08 in 2024, suggesting deteriorated profitability before a modest improvement expected at -€0.27 in 2026.

Early October Decline Following Roadmap Adjustment

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

In early October, the stock had suffered a significant decline following a roadmap adjustment. Paradoxically, the results for the first half of 2025 presented a more encouraging aspect, with sales increasing to €91.0 million from €68.3 million a year earlier. This discrepancy between improved operational fundamentals and deteriorating market dynamics fuels questions about the stock's trajectory.

Technical Analysis Confirms Intensity of Selling Pressure

Technical analysis confirms the intensity of the selling pressure. The RSI index established at 20 signals an extreme oversold zone, a configuration generally preceding a broader technical correction. The MACD line at -0.02 crosses its signal line downwards, forming a recessive signal, while the stochastic emits a strict sell signal. The stock is significantly below its 50-day moving average established at €4.29, confirming a short-term bearish orientation. Conversely, the 200-day moving average remains far behind at €3.32, providing a distant floor. The Bollinger Bands display significant amplitude, the lower band at €3.93 and the upper at €5.17, reflecting a significant monthly volatility of 16.12%. Cash flows record an accumulation of exits: the CMF (Chaikin Money Flow) at -0.07 and the OBV (On-Balance Volume) negative, translating ongoing liquidative pressure. This combination of degraded technical signals prevails a decidedly bearish sentiment in the short term, even though the proximity of the oversold zone could favor tactical rebounds.



Sector Santé · Pharmacie Industrie Pharmaceutique


Assurance vie

Context

Period
  • Period: 9M 2025
Guidance from the release
  • Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
  • Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
  • Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
  • Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
  • Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
  • Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
  • Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
  • Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
  • Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
  • Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
  • Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit